These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 27472514)
1. SUCCESSFUL TREATMENT OF REFRACTORY PROLIFERATIVE RETINOPATHY OF INCONTINENTIA PIGMENTI BY INTRAVITREAL RANIBIZUMAB AS ADJUNCT THERAPY IN A 4-YEAR-OLD CHILD. Ho M; Yip WWK; Chan VCK; Young AL Retin Cases Brief Rep; 2017 Fall; 11(4):352-355. PubMed ID: 27472514 [TBL] [Abstract][Full Text] [Related]
2. Revascularization After Intravitreal Bevacizumab and Laser Therapy of Bilateral Retinal Vascular Occlusions in Incontinentia Pigmenti (Bloch-Sulzberger Syndrome). Cernichiaro-Espinosa LA; Patel NA; Bauer MS; Negron CI; Fallas B; Pogrebniak A; Berrocal AM Ophthalmic Surg Lasers Imaging Retina; 2019 Feb; 50(2):e33-e37. PubMed ID: 30768227 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti. Ni Y; Huang X; Ruan L; Xue K; Yu J; Peng J; Zhao P J AAPOS; 2018 Aug; 22(4):325-327.e3. PubMed ID: 29630932 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor]. Wang X; Liang JH Zhonghua Yan Ke Za Zhi; 2019 Apr; 55(4):294-301. PubMed ID: 30982292 [No Abstract] [Full Text] [Related]
6. Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report. Kunzmann S; Ngyuen T; Stahl A; Walz JM; Nentwich MM; Speer CP; Ruf K BMC Pediatr; 2019 Oct; 19(1):353. PubMed ID: 31615465 [TBL] [Abstract][Full Text] [Related]
7. Serous retinal detachment after panretinal photocoagulation for proliferative diabetic retinopathy: a case report. Schatz P; Aldayel A; Taskintuna I; Abdelkader E; Mura M J Med Case Rep; 2017 Sep; 11(1):265. PubMed ID: 28923115 [TBL] [Abstract][Full Text] [Related]
8. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema. Mukkamala L; Bhagat N; Zarbin MA Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069 [TBL] [Abstract][Full Text] [Related]
9. Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy. Lucena CR; Ramos Filho JA; Messias AM; Silva JA; Almeida FP; Scott IU; Ribeiro JA; Jorge R Arq Bras Oftalmol; 2013; 76(1):18-20. PubMed ID: 23812521 [TBL] [Abstract][Full Text] [Related]
10. Optic nerve neovascularization in incontinentia pigmenti. Shah GK; Summers CG; Walsh AW; Neely KA Am J Ophthalmol; 1997 Sep; 124(3):410-2. PubMed ID: 9439375 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab. Rentiya ZS; Ferraz DA; Hutnik R; Bae J; Machado CG; Mucciolli C; Motta AALD; Ribeiro LZ; Guan Z; Preti RC; Takahashi WY Arq Bras Oftalmol; 2022; 85(1):37-45. PubMed ID: 34586227 [TBL] [Abstract][Full Text] [Related]
12. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288 [TBL] [Abstract][Full Text] [Related]
13. INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up. Arevalo JF; Lasave AF; Wu L; Maia M; Diaz-Llopis M; Alezzandrini AA; Brito M; Retina; 2017 Feb; 37(2):334-343. PubMed ID: 27429384 [TBL] [Abstract][Full Text] [Related]
14. Laser photocoagulation in preproliferative retinopathy of incontinentia pigmenti. Nguyen JK; Brady-Mccreery KM J AAPOS; 2001 Aug; 5(4):258-9. PubMed ID: 11507587 [TBL] [Abstract][Full Text] [Related]
15. Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study. Lang GE; Stahl A; Voegeler J; Quiering C; Zaremba L; Lorenz K; Spital G; Liakopoulos S Acta Ophthalmol; 2022 Mar; 100(2):e578-e587. PubMed ID: 34121335 [TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318 [TBL] [Abstract][Full Text] [Related]
17. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539 [TBL] [Abstract][Full Text] [Related]
18. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB. Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456 [TBL] [Abstract][Full Text] [Related]
19. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033 [TBL] [Abstract][Full Text] [Related]
20. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. Jang SY; Choi KS; Lee SJ J AAPOS; 2010 Oct; 14(5):457-9. PubMed ID: 21035077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]